Where the science of peptides becomes clear.
An education-first resource for clinicians, researchers, athletes, and curious readers exploring the modern peptide landscape, from GLP-1 agonists transforming obesity care to the regenerative and longevity peptides driving today's research conversations.
Browse by category
Explore the site
Peptides 96
Comprehensive individual peptide pages, mechanism, human and preclinical evidence, claims with verdicts, FAQs, references.
Browse peptides → Deepest hub on the siteGLP-1 Hub
Approved obesity and diabetes drugs, emerging incretin candidates, head-to-head comparisons, practical guides, and the trials reshaping the field.
Visit GLP-1 Hub → Practical guidesArticles 93
Comparison articles, side-effect timelines, practical strategies, and the questions people actually search for about GLP-1s and peptides.
Read articles → Theoretical combinationsStacks 40
Peptide combinations discussed in research and biohacker communities, with explicit evidence-grading and clear framing throughout.
Explore stacks → Calibrated takesEvidence vs Myth 26
Honest reads on contested claims, what the research actually shows, where the picture is promising, and where it's still being built.
Read clear takes → Frontier researchEmerging Peptides 34
Phase 3 candidates likely to reach market soon, mid-stage emerging compounds, and preclinical biology still years from clinical reality.
Track the frontier →Featured peptides
Semaglutide
Long-acting GLP-1 receptor agonist with FDA approvals across type 2 diabetes, obesity, and cardiovascular risk reduction.
Type 2 diabetes, Obesity and weight management
Tirzepatide
Dual GIP/GLP-1 receptor agonist, the first incretin co-agonist to reach the market.
Type 2 diabetes, Obesity and weight management
Retatrutide
Triple GIP / GLP-1 / glucagon receptor agonist, the next-generation incretin candidate.
Obesity (Phase 3), Type 2 diabetes (Phase 3)
BPC-157
A pentadecapeptide derived from a gastric protein, widely studied in animal models for tissue protection and recovery.
Tendon and ligament recovery research, Gut protection and inflammatory bowel models
PT-141
Melanocortin-receptor agonist acting centrally on the desire-and-arousal pathway.
Hypoactive sexual desire disorder (HSDD), FDA-approved, Erectile dysfunction (off-label and prior development)
Tesamorelin
FDA-approved GHRH analog, the most-evidence-supported growth-hormone-releasing peptide in clinical use
HIV-associated visceral adipose tissue (VAT) excess, FDA-approved indication, Non-alcoholic fatty liver disease in HIV+ populations, growing evidence
GHK-Cu
Glycyl-histidyl-lysine in complex with copper (II)
Cosmetic skin care (established), Wound healing (evidence)
MOTS-c
A 16-amino-acid peptide encoded within the mitochondrial genome, central to a new class of "mitokines."
Metabolic health and insulin sensitivity research, Exercise capacity and skeletal muscle adaptation
Established science
Peptides with multiple Phase 3 trials and regulatory approvals, including semaglutide, tirzepatide, tesamorelin, and PT-141, represent the strongest end of the evidence spectrum.
Start with semaglutide →Active research areas
BPC-157, TB-500, MOTS-c, epitalon and others sit in the active-research zone, promising mechanisms with growing animal data and emerging human trials.
See BPC-157 →Regulatory landscape
The FDA's evolving stance on compounded peptides shapes what's available and where. We summarize the current rules and what they mean for clinicians and researchers.
Read the context →In-depth reading
Semaglutide vs tirzepatide for weight loss
Head-to-head trial data, the GIP arm that makes tirzepatide deeper, the cardiovascular evidence each has, and which one fits which patient.
Read article ArticleGLP-1 side effects week by week
A practical timeline of what to expect through the typical 6-month dose-escalation pattern, plus the management strategies that actually help.
Read article ArticleHow to avoid muscle loss on GLP-1s
What the lean-mass-loss numbers actually mean, who's at highest risk, and the evidence-based interventions that reduce loss without slowing fat loss.
Read article ArticleBest peptide stacks for fat loss in 2026
Five stacks ranked by evidence, from CagriSema-level combinations to research-peptide tier with the honest verdict on each.
Read article Evidence vs MythThe BPC-157 tendon question
Sorting the substantial preclinical data from the persistent claim that BPC-157 has been clinically validated for tendon healing.
Read article Evidence vs MythDIHEXA: the "100,000× BDNF" claim examined
Where the assay-specific in-vitro potency finding came from, why the successor program disappointed in Phase 2/3, and the HGF/MET safety questions.
Read article GLP-1 HubSemaglutide vs tirzepatide vs retatrutide
The three leading incretin therapies, mechanism, weight-loss magnitude, side effects, and access, in head-to-head detail.
Read article GLP-1 HubLatest GLP-1 research
SELECT, FLOW, STEP-HFpEF, SURMOUNT-OSA, TRIUMPH, what the most recent landmark trials are showing.
Read articleHow we weigh evidence
Every claim on this site is anchored to a tier of evidence. We are clear about what is established, what is promising, and what is still developing, without dismissing reader interest or the genuine signals in early-stage research.